Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1984 Mar;81(5):1445–1447. doi: 10.1073/pnas.81.5.1445

Selective killing of Fc-receptor-bearing tumor cells through endocytosis of a drug-carrying immune complex.

W C Shen, H J Ryser
PMCID: PMC344852  PMID: 6369328

Abstract

A soluble immune complex was used as a drug carrier targeted to Fc-receptor-positive cells. Two receptor-positive tumor cell lines, WEHI-3 and M5076, were exposed to methotrexate-human serum albumin conjugate (MTX-HSA) in the presence and absence of anti-HSA antiserum. Both cell types were killed by 30 nM MTX when the drug conjugate was given in the presence of antiserum but were totally unaffected in the absence of antiserum. Drug-free HSA given with antiserum had no effect. Both cell lines responded similarly despite their marked difference in phagocytotic activity. One of the two lines, M5076, is defective in MTX transport and hence resistant to free MTX. Since this line would not be affected by MTX released extracellularly from MTX-HSA, its susceptibility implies that MTX is released inside cells, after endocytosis of the complex, and that endocytosis circumvents the transport defect. Two cell lines lacking Fc receptors (CHO and L929) were not influenced by the drug complex. The pharmacologic effect is mediated by a specific ligand-receptor interaction, since Fc receptor-positive cells are protected by an excess of unconjugated HSA and by the addition of a small amount of staphylococcal protein A, which binds to the Fc portion of IgG. These data demonstrate that Fc receptors can be exploited for cellular drug delivery using a common antigen-antibody complex as a drug carrier.

Full text

PDF
1445

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chu B. C., Whiteley J. M. The interaction of carrier-bound methotrexate with L1210 cells. Mol Pharmacol. 1980 May;17(3):382–387. [PubMed] [Google Scholar]
  2. Kerbel R. S., Elliott B. E. Detection of Fc receptors. Methods Enzymol. 1983;93:113–147. doi: 10.1016/s0076-6879(83)93038-0. [DOI] [PubMed] [Google Scholar]
  3. Langone J. J. Protein A of Staphylococcus aureus and related immunoglobulin receptors produced by streptococci and pneumonococci. Adv Immunol. 1982;32:157–252. [PubMed] [Google Scholar]
  4. Leserman L. D., Weinstein J. N., Blumenthal R., Terry W. D. Receptor-mediated endocytosis of antibody-opsonized liposomes by tumor cells. Proc Natl Acad Sci U S A. 1980 Jul;77(7):4089–4093. doi: 10.1073/pnas.77.7.4089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Muschel R. J., Rosen N., Bloom B. R. Isolation of variants in phagocytosis of a macrophage-like continuous cell line. J Exp Med. 1977 Jan 1;145(1):175–186. doi: 10.1084/jem.145.1.175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ryser H. J., Shen W. C. Conjugation of methotrexate to poly(L-lysine) increases drug transport and overcomes drug resistance in cultured cells. Proc Natl Acad Sci U S A. 1978 Aug;75(8):3867–3870. doi: 10.1073/pnas.75.8.3867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Shen W. C., Ryser H. J. Poly (L-lysine) and poly (D-lysine) conjugates of methotrexate: different inhibitory effect on drug resistant cells. Mol Pharmacol. 1979 Sep;16(2):614–622. [PubMed] [Google Scholar]
  8. Sirotnak F. M., Moccio D. M., Goutas L. J., Kelleher L. E., Montgomery J. A. Biochemical correlates of responsiveness and collateral sensitivity of some methotrexate-resistant murine tumors to the lipophilic antifolate, metoprine. Cancer Res. 1982 Mar;42(3):924–928. [PubMed] [Google Scholar]
  9. Talmadge J. E., Key M. E., Hart I. R. Characterization of a murine ovarian reticulum cell sarcoma of histiocytic origin. Cancer Res. 1981 Apr;41(4):1271–1280. [PubMed] [Google Scholar]
  10. Unkeless J. C., Fleit H., Mellman I. S. Structural Aspects and Heterogeneity of Immunoglobulin Fc Receptors. Adv Immunol. 1981;31:247–270. doi: 10.1016/s0065-2776(08)60922-0. [DOI] [PubMed] [Google Scholar]
  11. Unkeless J. C., Kaplan G., Plutner H., Cohn Z. A. Fc-receptor variants of a mouse macrophage cell line. Proc Natl Acad Sci U S A. 1979 Mar;76(3):1400–1404. doi: 10.1073/pnas.76.3.1400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Warner N. L., Moore M. A., Metcalf D. A transplantable myelomonocytic leukemia in BALB-c mice: cytology, karyotype, and muramidase content. J Natl Cancer Inst. 1969 Oct;43(4):963–982. [PubMed] [Google Scholar]
  13. Witz I. P. Tumor-bound immunoglobulins: in situ expressions of humoral immunity. Adv Cancer Res. 1977;25:95–148. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES